Announcing the Drug-Resistant Tuberculosis QuickFire Challenge

May 5, 2020 -
3 months ago
Other news

May 5, 2020 - Johnson & Johnson’s Global Public Health team, together with Johnson & Johnson Innovation – JLABS, are proud to introduce the DR-TB Lifeline QuickFire Challenge.

COVID-19 presents new challenges and concerns for DR-TB patients with respiratory impairment and/or lung damage may be more vulnerable to serious complications from COVID-19. Beyond individual vulnerability, the COVID-19 pandemic has seriously disrupted and weakened already-fragile systems of delivering care to DR-TB patients.

There is a clear need for community engagement and innovation with the aim to solve for the continuity of DR-TB services during the COVID-19 pandemic and after, as systems adopt and adapt to more virtual methods of care.

Community-based organizations, advocates and entrepreneurs are invited to submit potential solutions that will help ensure continuity of care for those diagnosed with and undergoing treatment for DR-TB. Specifically, we’re seeking ideas with the potential for patient impact in high-burden countries, including India, Indonesia, Philippines, South Africa, and South Africa.

Up to five innovators with the best ideas, technologies, or potential solutions will be awarded grant funding from a total of $250,000 *. Awardees will also have the opportunity to engage with experts at the Johnson & Johnson Family of Companies to help support bringing their ideas to life.

Apply at http://jlabs.tv/dr-tb by May 19, 2020.

* Up to $50,000 in grant funding each for up to five awardees

About Johnson & Johnson’s Global Public Health

Charting a bold new, self-sustainable approach, Johnson & Johnson has established the first fully-dedicated organization within a healthcare company focused on combining innovative R&D, novel access programs & approaches, in-country operations, advocacy and the power of multi-sectoral partnerships to ensure that treatments and technologies are available, affordable and accessible for the world's most under-served populations. Harnessing the extensive resources and expertise from across Johnson & Johnson, its Global Public Health team is placing an unparalleled focus on accelerating the pace of innovation needed – from discovery to delivery – to make TB and HIV history, eliminate intestinal worms, address mental health and wrestle other public health challenges. Learn more at www.jnj.com/global-public-health and follow us @JNJGlobalHealth.

About Johnson & Johnson Innovation 

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com .

About Johnson & Johnson Innovation - JLABS

Johnson & Johnson InnovationJLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS. 

 


Related content